# OnCo record paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020" ;
  schema:name "Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial"@en ;
  schema:description "In 196 women with triple-negative breast cancer left with residual tumour after pre-surgery chemotherapy, finding tumour DNA in the blood after surgery tripled the risk of distant relapse and quadrupled the risk of death; at two years 56 percent versus 81 percent were free of distant disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2020.2295>, <https://pubmed.ncbi.nlm.nih.gov/32644110/>, <https://clinicaltrials.gov/study/NCT02101385> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2020.2295> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Radovich M, Jiang G, Hancock BA, et al." ;
  onco:related <https://onco.cc/roadmaps/ctdna-tests/>, <https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/>, <https://onco.cc/biomarkers/ctdna-mrd-positive/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:companies <https://onco.cc/companies/foundation-medicine/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .